Breakingviews

Pfizer yet to land knockout blow on Astra

May 2, 2014

The U.S. drugmaker upped its proposal to $106 bln, and promised to keep some of the UK group’s workforce. It does not look high enough to bring Astra to the table. Worse, Pfizer’s aggressive public tactics may only antagonise shareholders.

Astra has small tactical advantage over Pfizer

May 1, 2014

Time can benefit bidders rather than targets – that’s why Kraft left Cadbury flailing for months. But uncertainties around regulatory clearance and Washington politics complicate the dynamics of Pfizer’s approach to AstraZeneca. The U.S. group will want a quick, recommended deal.

Review: Embracing the psychopath within

November 9, 2012

“The Wisdom of Psychopaths” is a good read lurking within a bad one. Amidst the showboating, Kevin Dutton’s book mines brain science to make a cogent case that some psychopathic traits - seen in CEOs, traders and monks as well as serial killers - are not only necessary, but good.

Leave it to a hedgie to take on Einstein

June 7, 2013

A brainiac hedge fund manager thinks he has cracked one of physics’ biggest mysteries. Scientists are sceptical, but admit Eric Weinstein’s ideas deserve study. Even if he is wrong, it’s nice for once to see a Wall Street boffin apply his skills to questions of beauty and truth.